BioCentury
ARTICLE | Company News

Celgene, NantWorks deal

January 20, 2014 8:00 AM UTC

Celgene partnered with the NantBioscience subsidiary of Patrick Soon-Shiong's NantWorks to develop a pipeline of cancer drugs using the nanoparticle albumin-bound (nab) technology Celgene gained in its acquisition of Soon-Shiong's former company, Abraxis Bioscience Inc. The deal includes rights to two preclinical compounds - NTB-011 (formerly AB-011), a nab formulation of a colchicine dimer, and NTB-010 (formerly AB-010), a nab formulation of the geldanomycin analogue 17- AAG. The deal is expected to close this quarter (see BioCentury, July 5, 2010 & October 18, 2010). ...